Curatis Holding AG (CURN.SW) Friday said that it has entered into a definitive agreement with a Swiss investor for a private placement of a 1.2 million Swiss francs convertible instrument.
The specialty pharmaceutical company said that as per terms of the agreement, the investor will subscribe to a convertible instrument, which can be converted into shares of Curatis Holding, with the shares expected to be issued from its conditional capital.
The instrument has been priced in line with existing market conditions and the transaction is anticipated to close in the next few days, subject to customary conditions, the company said in an official statement.
According to Curatis Holding, the proceeds from this financing will support and accelerate the development of its late-stage clinical lead product candidate, corticorelin.
On the Swiss Exchange, CURN.SW ended Thursday's trading at 12.85 Swiss francs, down 0.05 francs or 0.39 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.